top of page

Biotech CEO Sisterhood: Gallop Oncology CEO Luba Greenwood on the importance of the Sisterhood, the Massachusetts life sciences ecosystem, and Gallop's work

blonca9
Mar 27
1 min read

Interviewed by Normunity CEO Rachel Humphrey at MassBio's 2025 State of Possible Conference, Luba explains how the Sisterhood arms members with important information, she shares the impression of the Massachusetts ecosystem she has gained as a MassBio board member, and also describes the effort against cancer at Gallop that motivates her each day.

Recent Posts

Biotech CEO Sisterhood: EpiBone creates bones and cartilage grown from stem cells - Co-Founder and CEO Nina Tandon describes the creative thinking she has used to accelerate its availability

Biotech CEO Sisterhood: EpiBone creates bones and cartilage grown from stem cells - Co-Founder and CEO Nina Tandon describes the creative thinking she has used to accelerate its availability

Biotech leader Sheila Gujrathi discusses her new book, The Mirror Effect, which she wrote for her younger self, today's peers, and the next generation of female leaders in business

Biotech leader Sheila Gujrathi discusses her new book, The Mirror Effect, which she wrote for her younger self, today's peers, and the next generation of female leaders in business

Biotech CEO Sisterhood: Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that led to the first approved therapy for Barth Syndrome

Biotech CEO Sisterhood: Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that led to the first approved therapy for Barth Syndrome

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page